Overview
The study aims to compare permanent Conduction System Pacing (CSP) with the standard therapy - Right Ventricular Pacing (RVP) or Biventricular Pacing (BVP) - in preventing the development and progression of symptomatic Chronic Heart Failure (CHF) and improving survival in patients after Transcatheter Aortic Valve Implantation (TAVI).
Description
A multicenter randomized controlled head-to-head trial was planned to compare the effects of permanent pacemaker implantation (PPMI) using CSP (study intervention) with currently standard therapy - RVP or BVP (control group). The study population will consist of patients hospitalized after TAVI complicated with high-degree persistent atrioventricular (AV) block or newly developed complex AV or intraventricular conduction disturbances, qualified for PPMI within 30 days after surgery, following the 2021 European Society of Cardiology (ESC) guidelines on cardiac pacing and cardiac resynchronization therapy.
Eligibility
Inclusion Criteria:
- transcatheter aortic valve implantation (TAVI) in up to 30 days before qualification to pacemaker implantation
- Fulfilled criteria for permanent pacemaker implantation according do 2021 ESC guidelines
- Written informed consent
- Age of at least 18 years
Exclusion Criteria:
- Permanent pacemaker implantation before TAVI procedure
- The occurrence of conduction disturbances more than 30 days after TAVI procedure
- No written informed consent
- Inability to obtain informed consent from participant
- Predicted inability to obtain cooperation from patient during observation period